Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy

Phase 1

• Conditions: Hepatocellular Carcinoma
• Interventions: Drug: CpG DNA; Procedure: transcatheter arterial chemoembolization; Drug: Placebo - Concentrate

• Registration Number: NCT03235167
• Lead Sponsor: Dalian University

Brief Summary

to observe the outcome of hepatocellular carcinoma patients under the combination treatment of transcatheter arterial chemoembolization (TACE) and CpG DNA

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-07-27
• Study First Submitted QC: 2017-07-27
• Study First Posted: 2017-08-01
• Status Verified: 2017-09
• Last Update Submitted: 2017-09-14
• Last Update Posted: 2017-09-18
• Study Start: 2017-10
• Primary Completion: 2022-10
• Study Completion: 2022-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• TNM (tumor node metastasis ) staging with non distant metastasis; no other tumors

Exclusion Criteria

• having received previous treatment for liver cancer

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL

Arm && Interventions

Group	Intervention	Description
CpG DNA	transcatheter arterial chemoembolization	CpG DNA concentrate
placebo	Placebo - Concentrate	placebo concentrate
CpG DNA	CpG DNA	CpG DNA concentrate
placebo	transcatheter arterial chemoembolization	placebo concentrate

Primary Outcome Measures

Name	Time	Method
survival time	5 years
metastasis free survival time	5 years